首页(Home)
品牌专区(Brands-parters)
//自动完成提示
function beginSearch() {
if (document.getElementById("Keyword").value.replace(/(^\s*)|(\s*$)/g, "").length > 2) {
$("#divMsg").html("");
var tbSearch = document.getElementById("Keyword").value;
var div_msg = document.getElementById("divMsg");
div_msg.style.display = "block";
$.ajax({
type: "post",
dataType: "json", //数据格式:JSON
url: "/tools/submit_ajax.ashx?action=zhitishi",
data: { father: tbSearch },
async: false,
success: function (data) {
var str = "";
var str1 = "";
var str2 = "";
var str3 = "";
var SupplyType = data.SupplyType; //供应品类列表
var Brands = data.Brands; //品牌列表
var ProductStyle = data.ProductStyle; //产品列表
var str0 = "";
if (SupplyType != null && SupplyType != "") {
str0 += " EntreMed www.entremed.com 英创远达(北京)生物医药科技有限公司 Investor Relations供应分类";
$.each(SupplyType, function () {//遍历Specification
str0 += "";
});
}
if (ProductStyle != null && ProductStyle != "") {
str1 += "产品分类";
$.each(ProductStyle, function () {//遍历ProductType
str1 += "";
});
}
if (Brands != null && Brands != "") {
str2 = "品牌";
$.each(Brands, function () {//遍历Brands
str2 += "";
});
}
str = str0 + str2 + "";
$("#divMsg").html(str);
}
});
}
else if (document.getElementById("Keyword").value.replace(/(^\s*)|(\s*$)/g, "").length == 0) {
var div_msg = document.getElementById("divMsg");
div_msg.style.display = "none";
div_msg.innerHTML = "";
}
}
EntreMed, Inc. 是一家致力于开发 ENMD-2076 的临床阶段制药公司。ENMD-2076 是用于治疗癌症的选择性血管生成激酶抑制剂。ENMD-2076 目前正在进行一项多中心二期卵巢癌研究，并且已经完成了多个有关实体肿瘤、多发性骨髓瘤和白血病的一期研究
EntreMed, Inc.
9640 Medical Center Drive
Rockville, MD 20850
Phone: (240) 864-2600
Fax: (301) 315-2437
EntreMed (Beijing), Inc.
Hanhai Culture Plaza Suite 716
Building 28-1
Xiang Jun Bei Li
Chaoyang District
Beijing 100025
P. R. China
(240) 864-2643
investorrelations@entremed.com
EntreMed, Inc. is a clinical-stage pharmaceutical company employing a drug development strategy primarily in the United States and China to develop targeted therapeutics for the global market. Its lead compound, ENMD-2076, a selective angiogenic kinase inhibitor, has completed several Phase 1 studies in solid tumors, multiple myeloma, and leukemia, and is currently completing a multi-center Phase 2 study in ovarian cancer. EntreMed, Inc. recently initiated a Phase 2 study of ENMD-2076 in triple-negative breast cancer.
